Novel coronavirus Non Replicating Viral Vector vaccine from Cansino

CanSino Biologics Inc.

Beijing Institute of Biotechnology

Clinical  Stage:phase 3

Vaccine platform:Non Replicating Viral Vector

Type of candidate vaccine: Adenovirus Type 5 Vector

Number of doses:1

Route of Administration: IM

Phase 3 report:

Phase 2 report:

Phase 1 report: